153 related articles for article (PubMed ID: 20374036)
21. In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Gupta A; Le A; Belinka BA; Kachlany SC
Leuk Res; 2011 Nov; 35(11):1498-505. PubMed ID: 21664691
[TBL] [Abstract][Full Text] [Related]
22. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
23. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H
Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875
[TBL] [Abstract][Full Text] [Related]
24. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
Jakubowska J; Wasowska-Lukawska M; Czyz M
Eur J Pharmacol; 2008 Oct; 596(1-3):41-9. PubMed ID: 18782571
[TBL] [Abstract][Full Text] [Related]
25. Honokiol up-regulates prostacyclin synthease protein expression and inhibits endothelial cell apoptosis.
Zhang X; Chen S; Wang Y
Eur J Pharmacol; 2007 Jan; 554(1):1-7. PubMed ID: 17109844
[TBL] [Abstract][Full Text] [Related]
26. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death.
Tian W; Deng Y; Li L; He H; Sun J; Xu D
Int J Oncol; 2013 Feb; 42(2):721-32. PubMed ID: 23242346
[TBL] [Abstract][Full Text] [Related]
27. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.
Tse AK; Wan CK; Shen XL; Yang M; Fong WF
Biochem Pharmacol; 2005 Nov; 70(10):1443-57. PubMed ID: 16181613
[TBL] [Abstract][Full Text] [Related]
28. Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules.
Jeong JJ; Lee JH; Chang KC; Kim HJ
Int J Oncol; 2012 Oct; 41(4):1358-64. PubMed ID: 22895699
[TBL] [Abstract][Full Text] [Related]
29. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
Zhang K; Xu J; Huang X; Wu L; Wen C; Hu Y; Su Y; Chen Y; Zhang Z
Cancer Chemother Pharmacol; 2007 Sep; 60(4):581-7. PubMed ID: 17435997
[TBL] [Abstract][Full Text] [Related]
30. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
31. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
[TBL] [Abstract][Full Text] [Related]
33. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
[TBL] [Abstract][Full Text] [Related]
34. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
35. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
36. Differential proteomic analysis of HeLa cells treated with Honokiol using a quantitative proteomic strategy.
Ling B; Liang SF; Xu YH; Zhao XY; Tang MH; Liu XY; Zhao X; Huang CH; Chen LJ; Wei YQ
Amino Acids; 2008 Jun; 35(1):115-22. PubMed ID: 18157584
[TBL] [Abstract][Full Text] [Related]
37. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
38. Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction.
Li XQ; Ren J; Wang Y; Su JY; Zhu YM; Chen CG; Long WG; Jiang Q; Li J
Cell Oncol (Dordr); 2021 Feb; 44(1):135-150. PubMed ID: 32936421
[TBL] [Abstract][Full Text] [Related]
39. [Honokiol-induced apoptosis of human non-Hodgkin lymphoma Raji cells and its possible mechanism].
Chen W; Lin GW; Zhang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1918-21. PubMed ID: 22126780
[TBL] [Abstract][Full Text] [Related]
40. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
